LDX Share Price Performance
AU$0.12
0.01 (9.52%)
67.1% undervalued intrinsic discount
AU$0.35
Fair Value
Price AU$0.12
AnalystHighTarget AU$0.35
AnalystConsensusTarget AU$0.28
Fair ValueAU$0.35
Share Pricen/a
New Narrative • Aug 01
Lumos Diagnostics Holdings Limited Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 16 Fair Values set on narratives written by author
LDX Community Narratives
AN
Fair Value
·Fair Value AU$0.35 67.1% undervalued intrinsic discount
Bullish View Expects CLIA Waiver And PHASE Contract To Drive Long-Term Upside
1users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value
·Fair Value AU$0.28 58.9% undervalued intrinsic discount
Antibiotic Stewardship And CLIA Waiver Progress Will Shape This Fairly Valued Outlook
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
Bullish View Expects CLIA Waiver And PHASE Contract To Drive Long-Term Upside
Lumos Diagnostics is betting big on FebriDx in U.S. urgent care, with a key regulatory green light and a large distribution deal that could bring steadier demand. The upside hinges on clinics adopting the test widely and insurers continuing to pay for it—while shifts in testing habits or weaker follow-through from partners could derail the story.Read more
AN
AU$0.35
67.1% undervalued intrinsic discount
Fair Value
Profit Margin
8.93%
Future PE
86.89x
Price in 2029
AU$0.44
Antibiotic Stewardship And CLIA Waiver Progress Will Shape This Fairly Valued Outlook
Catalysts About Lumos Diagnostics Holdings Lumos Diagnostics Holdings focuses on point of care diagnostic tests that aim to support real time treatment decisions for physicians and patients. What are the underlying business or industry changes driving this perspective?Read more
AN
AU$0.28
58.9% undervalued intrinsic discount
Fair Value
Profit Margin
11.21%
Future PE
48.92x
Price in 2029
AU$0.35
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
Bullish View Expects CLIA Waiver And PHASE Contract To Drive Long-Term Upside
Fair Value: AU$0.35 67.1% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Antibiotic Stewardship And CLIA Waiver Progress Will Shape This Fairly Valued Outlook
Fair Value: AU$0.28 58.9% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Lumos Diagnostics Holdings Limited Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.0098
- 62.17%
- -75.81%
- 0%
About LDX
- Founded
- 2018
- Employees
- n/a
- CEO
- WebsiteView website
Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company’s products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos Diagnostics Holdings Limited was incorporated in 2018 and is based in Carlsbad, California.
